“Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s135. doi:10.25251/skin.7.supp.135.